Pulmonary fibrosis as an outcome of COVID-19 pneumonia
https://doi.org/10.29235/1814-6023-2021-18-4-413-421
Abstract
In this study, we report three cases of persistent severe respiratory failure and radiological signs of diffuse pulmonary fibrosis in patients after COVID-19 related pneumonia. Chest CT criteria for a diagnosis of pulmonary fibrosis include the presence of traction bronchiectasis and parenchymal bands (linear opacities), as well as numerous small subpleural cystic air spaces (honeycombing). The study found that all cases of fibrosis were associated with such risk factors as male gender, old age, and multicomorbidity. Chest CT of one patient with acute respiratory distress syndrome showed radiographic characteristics of pulmonary fibrosis together with the presence of ground glass opacities (GGO) – the main CT feature of COVID-19 pneumonia. In two other patients, CT features of pulmonary fibrosis appeared in about 2 months after the hospital stay.
Thus, pulmonary fibrosis is severe and rapidly progressive complication of COVID-19 pneumonia with a poor prognosis, especially in patients with multiple risk factors.
About the Authors
T. I. Kalenchic
Belarusian State Medical University
Russian Federation
Russian Federation
Tamara I. Kalenchic – Ph. D.(Med.), Associate Professor
83, Dzerzhinski Ave., 220116, Minsk
S L. Kabak
Belarusian State Medical University
Russian Federation
Russian Federation
Sergey L. Kabak – Ph. D. (Med.), Professor
83, Dzerzhinski Ave., 220116, Minsk
I. V. Korenevskaya
6th City Clinical Hospital
Russian Federation
Russian Federation
Inna V. Korenevskaya – pulmonologist
5, Ural’skaya Str., 220037, Minsk
References
1. Ojo A. S., Balogun S. A, Williams O. T., Ojo O. S. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulmonary Medicine, 2020, vol. 2020, art. ID 6175964. https://doi.org/ 10.1155/2020/6175964
2. Vitiello A., Pelliccia C., Ferrara F. COVID-19 patients with pulmonary fibrotic tissue: clinical pharmacological rational of antifibrotic therapy. SN Comprehensive Clinical Medicine, 2020, vol. 2, no. 10, pp. 1709–1712. https://doi.org/10.1007/ s42399-020-00487-7
3. Ahmad Alhiyari M., Ata F., Islam Alghizzawi M., Bint I., Bilal A., Salih Abdulhadi A., Yousaf Z. Post COVID-19 fibrosis, an emerging complication of SARS-CoV-2 infection. IDCases, 2020, vol. 23, p. e01041. https://doi.org/10.1016/j. idcr.2020.e01041
4. Rai N., Baidya D. K. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic: is sequela the bigger threat? Indian Journal of Critical Care Medicine, 2021, vol. 25, no. 2, pp. 245–246. https://doi.org/10.5005/jp-journals-10071-23734
5. McGroder C. F., Zhang D., Choudhury M. A., Salvatore M. M., D’Souza B. M., Hoffman E. A., Wei Y., Baldwin M. R., Garcia C. K. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax, 2021. https://doi.org/10.1136/thoraxjnl-2021-217031
6. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. [et al.]. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine, 2020, vol. 180, no. 7, pp. 934–943. https://doi.org/934–943. 10.1001/jamainternmed.2020.0994
7. Combet M., Pavot A., Savale L., Humbert M., Monnet X. Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. European Respiratory Journal, 2020, vol. 56, no. 2, p. 2001808. https://doi.org/ 10.1183/13993003.01808-2020
8. Speranskaya A. A. Radiological signs of a new coronavirus infection COVID-19. Luchevaya diagnostika i terapiya = Diagnostic radiology and radiotherapy, 2020, vol. 11, no. 1, pp. 18–25 (in Russian).
9. Ye Z., Zhang Y., Wang Y., Huang Z., Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. European Radiology, 2020, vol. 30, no. 8, pp. 4381–4389. https://doi.org/10.1007/s00330-020-06801-0
10. Pan Y., Guan H., Zhou S., Wang Y., Li Q., Zhu T., Hu Q., Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. European Radiology, 2020, vol. 30, no. 6, pp. 3306–3309. https://doi.org/10.1007/s00330-020-06731-x
11. Karnaushkina M. A., Aver’yanov A. V., Lesnyak V. N. Ground glass opacities on CT of the chest in the practice of the clinician: pathogenesis, significance, differential diagnose. Arkhiv vnutrennei meditsiny [The Russian archives of internal medicine], 2018, vol. 8, no. 3, pp. 165–175 (in Russian).
12. Murkamilov I. T., Sabirov I. S., Fomin V. V., Aitbaev K. A., Yusupov F. A. Idiopathic pulmonary fibrosis: prevalence and risk factors (literature review). Scientific Heritage, 2020, vol. 49, no. 2, pp. 41–48 (in Russian).
13. Chuchalin A. G., Avdeev S. N., Aisanov Z. R., Belevskii A. S., Demura S. A., Il’kovich M. M. [et al.]. Diagnosis and treatment of idiopathic pulmonary fibrosis. federal guidelines. Pul’monologiya [Pulmonology], 2016, vol. 26, no. 4, pp. 399– 419 (in Russian).
14. Ali R. M. M., Ghonimy M. B. I. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egyptian Journal of Radiology and Nuclear Medicine, 2021, vol. 52, no. 1, art. 101. https://doi.org/10.1186/s43055-021-00484-3
15. Naik P. K., Moore B. B. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Review of Respiratory Medicine, 2010, vol. 4, no. 6, pp. 759–771. https://doi.org/ 10.1586/ers.10.73
16. George P. M., Wells A. U., Jenkins R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine, 2020, vol. 8, no. 8, pp. 807–881. https://doi.org/10.1016/S2213-2600(20)30225-3
17. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. [et al.]. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395, no. 10229, pp. 1054–1062. https://doi. org/10.1016/S0140-6736(20)30566-3
18. Upadhya P., Chary R., Chawla G., Vadala R., Mohanty M. New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis. Advances in Respiratory Medicine, 2021, vol. 89, no. 1, pp. 84–85. https://doi.org/ 10.5603/ARM.a2020.0177
19. Brereton C. J., Jo H. E. Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids. Breathe, 2020, vol. 16, no. 3, pp. 1–4. https://doi.org/10.1183/20734735.0086-2020
Review
For citations:
Kalenchic T.I., Kabak S.L., Korenevskaya I.V. Pulmonary fibrosis as an outcome of COVID-19 pneumonia. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(4):413-421. (In Russ.) https://doi.org/10.29235/1814-6023-2021-18-4-413-421
Views: 789
Email this article 